Qing Xi Ooi supports clients with hands-on analysis and strategic advice

Viviana Moroso brings scientific depth to quality control

Siv Jönsson develops Pharmetheus’s learning agenda
Events
News

Contact us

Home
About us
People

Céline Sarr

Céline Sarr, Ph.D.

Principal Director, MIDD Consultant

Google scholar

Joined Pharmetheus in 2016, actively working in client projects, leading the Client Operations Forum, and serving as Project Portfolio Team Leader
Expertise includes pharmacometrics, submission, pediatric investigation plans, and MIDD support in therapeutic areas such as oncology and metabolism disorders
Previously worked as Senior Consultant at SGS-Exprimo, Belgium, where she delivered modeling results to support submissions and internal decisions, as Senior Expert Modeler at Novartis, Switzerland, Cluster Leader at Novartis, USA, and Modeler at Novartis, Switzerland
Pharm.D. (2004) from University Paris XII, France, and Ph.D. in Pharmaceutical Biosciences (2006) from University Lyon Claude Bernard, France

Pharmetheus affiliated publications

Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on Phase I data Dose Modifications in Exposure-Response Analyses of Oncology Drug Development: Brigimadlin Case Study Application of model-informed drug development for dose optimization of brigimadlin in patients with dedifferentiated liposarcoma Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection Integrated modeling of biomarkers, survival and safety in clinical oncology drug development Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder Application of tumor size modelling and simulations to support the dose selection of BI 907828 for a Phase II study Population PK analysis of Pegaspargase in Japanese and non-Japanese patients with acute lymphoblastic leukemia A framework for prediction of progression free survival based on modelling of sub-endpoints How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example Exposure–Safety Analyses of Nintedanib in Patients with Chronic Fibrosing Interstitial Lung Disease The Standard Output: A Tool-Agnostic Modeling Storage Format Open Innovation: Towards Sharing of Data, Models and Workflows

Contact

Pharmetheus AB
Kungsängstull 4  
753 19 Uppsala, Sweden

Visiting address:  
Dragarbrunnsgatan 77, 5th floor

LinkedIn
YouTube

Services & Science
Quick links

About Pharmetheus

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.

Whistleblower
Privacy Policy
Cookie Policy